Good morning, you're tuned in to Markets Desk.
All eyes are on Micron ahead of next week's earnings report, where Rosenblatt analysts expect the memory chipmaker to announce new customer agreements, improving average selling prices, and a potential return of capital through stock buybacks. With AI-driven memory demand accelerating, the stakes for this print are genuinely high.
Shifting to the retail space, HSBC upgraded Dollar General to Buy from Hold on September twenty-fourth, two thousand twenty-six, citing the discount chain's ongoing operational focus across its network of more than eighteen thousand stores in forty-seven states. The call signals growing confidence that value-oriented consumers remain a durable tailwind for the sector.
And in biotech, Vistagen reported positive exploratory findings for its intranasal compound Fasedienol in patients with very severe social anxiety disorder. The company, which is developing a novel class of pherines, says the data supports continued advancement of the treatment, a meaningful catalyst for a late clinical-stage name that has been closely watched by specialty pharma investors.
That's the tape. Markets Desk, signing off the floor.
